GSK plc (GLAXF) Financials
GLAXF Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 81.2 billion | 58.6 billion |
| March 31, 2026 | 83.0 billion | 60.0 billion |
| Dec. 31, 2025 | 82.1 billion | 60.6 billion |
| Sept. 30, 2025 | 82.5 billion | 61.3 billion |
GLAXF Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | 2.9 billion | ? |
| March 31, 2026 | 921.4 million | ? |
| Dec. 31, 2025 | 2.0 billion | ? |
| Sept. 30, 2025 | 2.6 billion | ? |
GLAXF Net Income
| Date | Net Income |
|---|---|
| June 30, 2026 | 572.1 million |
| March 31, 2026 | 2.4 billion |
| Dec. 31, 2025 | 854.5 million |
| Sept. 30, 2025 | 2.7 billion |
GLAXF Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 4.1 billion | 18.3 billion | - |
| March 31, 2026 | 4.5 billion | 18.5 billion | - |
| Dec. 31, 2025 | 4.6 billion | 19.8 billion | 1.1 billion |
| Sept. 30, 2025 | 4.4 billion | 20.0 billion | - |
GLAXF Shares Outstanding
GLAXF Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 431.4 million | 2.3 billion | 2.9 billion | - |
| March 31, 2026 | 584.8 million | 2.2 billion | 2.8 billion | - |
| Dec. 31, 2025 | 769.9 million | 3.1 billion | 3.6 billion | - |
| Sept. 30, 2025 | 432.7 million | 1.7 billion | 2.3 billion | - |
GLAXF Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 11.1 billion | 2.8 billion |
| March 31, 2026 | 10.1 billion | 2.5 billion |
| Dec. 31, 2025 | 11.6 billion | 3.5 billion |
| Sept. 30, 2025 | 8.6 billion | 2.3 billion |
GLAXF
Price: $22.77
Dividend Yield: 3.61%
Payout Ratio: 51.48%
Earnings Per Share: 1.57 USD
P/E Ratio: 16.38
Exchange: PNK
Sector: Healthcare
Industry: Drug Manufacturers - General
Country: United Kingdom
Market Capitalization: 101.0 billion
Average Dividend Frequency: 8
Years Paying Dividends: 23
DGR3: 13.82%
DGR5: 6.76%
DGR10: 1.46%
DGR20: 6.10%